XML 23 R12.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

REVENUE (Notes) | 9 Months Ended
--- | ---
Jul. 31, 2024
Revenue from Contract with Customer [Abstract] |
Revenue from Contract with Customer | REVENUE The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:
| Three Months Ended July 31,
| 2024 |  | 2023
| Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total |  | Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 251 |  |  | $ | 170 |  |  | $ | 205 |  |  | $ | 626 |  |  | $ | 270 |  |  | $ | 159 |  |  | $ | 238 |  |  | $ | 667 |
Europe | 193 |  |  | 113 |  |  | 126 |  |  | 432 |  |  | 203 |  |  | 108 |  |  | 121 |  |  | 432 |
Asia Pacific | 338 |  |  | 128 |  |  | 54 |  |  | 520 |  |  | 381 |  |  | 129 |  |  | 63 |  |  | 573 |
Total | $ | 782 |  |  | $ | 411 |  |  | $ | 385 |  |  | $ | 1,578 |  |  | $ | 854 |  |  | $ | 396 |  |  | $ | 422 |  |  | $ | 1,672 |
| Nine Months Ended July 31,
| 2024 |  | 2023
| Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total |  | Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 735 |  |  | $ | 501 |  |  | $ | 657 |  |  | $ | 1,893 |  |  | $ | 819 |  |  | $ | 467 |  |  | $ | 744 |  |  | $ | 2,030 |
Europe | 605 |  |  | 335 |  |  | 376 |  |  | 1,316 |  |  | 649 |  |  | 309 |  |  | 363 |  |  | 1,321 |
Asia Pacific | 1,042 |  |  | 382 |  |  | 176 |  |  | 1,600 |  |  | 1,203 |  |  | 388 |  |  | 203 |  |  | 1,794 |
Total | $ | 2,382 |  |  | $ | 1,218 |  |  | $ | 1,209 |  |  | $ | 4,809 |  |  | $ | 2,671 |  |  | $ | 1,164 |  |  | $ | 1,310 |  |  | $ | 5,145 |
The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
| Three Months Ended |  | Nine Months Ended
| July 31, |  | July 31,
| 2024 |  | 2023 |  | 2024 |  | 2023
| (in millions)
Revenue by End Markets |  |  |  |  |  |  |
Pharmaceutical | $ | 540 |  |  | $ | 592 |  |  | $ | 1,647 |  |  | $ | 1,843 |
Chemicals and Advanced Materials | 356 |  |  | 378 |  |  | 1,110 |  |  | 1,162 |
Diagnostics and Clinical | 242 |  |  | 241 |  |  | 709 |  |  | 730 |
Food | 144 |  |  | 151 |  |  | 440 |  |  | 472 |
Academia and Government | 128 |  |  | 146 |  |  | 417 |  |  | 451 |
Environmental and Forensics | 168 |  |  | 164 |  |  | 486 |  |  | 487 |
Total | $ | 1,578 |  |  | $ | 1,672 |  |  | $ | 4,809 |  |  | $ | 5,145 |
Revenue by Type |  |  |  |  |  |  |
Instrumentation | $ | 556 |  |  | $ | 643 |  |  | $ | 1,734 |  |  | $ | 2,091 |
Non-instrumentation and other | 1,022 |  |  | 1,029 |  |  | 3,075 |  |  | 3,054 |
Total | $ | 1,578 |  |  | $ | 1,672 |  |  | $ | 4,809 |  |  | $ | 5,145 |
Revenue by region is based on the ship to location of the customer. Revenue by end market is determined by the market indicator of the customer and by customer type. Instrumentation revenue includes sales from instruments, remarketed instruments and third-party products. Non-instrumentation and other revenue include sales from contract and per incident services, our companion diagnostics and our nucleic acid solutions businesses as well as sales from spare parts, consumables, reagents, vacuum pumps, subscriptions, software licenses and associated services. Contract Balances Contract Assets Contract assets (unbilled accounts receivable) primarily relate to the company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are reclassified to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the condensed consolidated balance sheet. The balances of contract assets as of July 31, 2024 and October 31, 2023, were $244 million and $252 million, respectively. Contract Liabilities The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the nine months ended July 31, 2024:
|  | Contract Liabilities
|  | (in millions)
Ending balance as of October 31, 2023 |  | $ | 616 |
Net revenue deferred in the period |  | 456 |
Revenue recognized that was included in the contract liability balance at the beginning of the period |  | (422) |
Change in deferrals from customer cash advances, net of revenue recognized |  | (8) |
Currency translation and other adjustments |  | 4 |
Ending balance as of July 31, 2024 |  | $ | 646 |
During the nine months ended July 31, 2023 revenue recognized that was included in the contract liability balance at October 31, 2022 was $368 million. Contract liabilities primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either current in deferred revenue or long-term in other long-term liabilities in the condensed consolidated balance sheet based on the timing of when we expect to complete our performance obligation. Contract Costs Incremental costs of obtaining a contract with a customer are recognized as an asset if we expect the benefit of those costs to be longer than one year. We have determined that certain sales incentive programs meet the requirements to be capitalized. The change in total capitalized costs to obtain a contract was immaterial during the three and nine months ended July 31, 2024, and was included in other current and long-term assets on the condensed consolidated balance sheet. We have applied the practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the company's internal sales force compensation program, as we have determined that annual compensation is commensurate with annual sales activities. Transaction Price Allocated to the Remaining Performance Obligations We have applied the practical expedient in ASC 606-10-50-14 and have not disclosed information about transaction price allocated to remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized for remaining performance obligations that have an original term of more than one year, as of July 31, 2024, was $344 million, the majority of which is expected to be recognized over the next 12 months. Remaining performance obligations primarily include extended warranty, customer manufacturing contracts, software maintenance contracts and revenue associated with lease arrangements.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration